Case Study — South Korean Patients with Esophageal Cancer — Oncology & Gene Therapy

Key Takeaways

BBK was engaged to support the enrollment of a study in South Korea evaluating a PD-1 immune checkpoint inhibitor in patients with esophageal cancer refractory or intolerant to common treatment.

Because of concerns about sharing patient information, the strategy shifted from generating patient referrals to focusing on physician awareness in an effort to inform relevant physicians about the study. In all key benchmarks, BBK met or exceeded the client’s expectations, and resulted in identifying 27 physicians interested in referring one or more patients to the study.

105 BBK identified, evaluated and reached out to 105 physicians who specialize in esophageal cancer in South Korea.
157 BBK conducted 157 phone calls with physicians and site staff to raise awareness about the study and to encourage them to refer.
80 In just six weeks, our physician website logged 80 sessions from 47 unique users, with an average time spent of nearly four minutes per visit.
27 Twenty-seven physicians expressed interest in referring one or more of their patients to the study, exceeding client expectations.